EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Real‐World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort

Real-World-Wirksamkeit und Behandlungsmuster von Tirzepatid in einer großen britischen digitalen Gesundheitskohorte

Onayomi Rosenior-Patten iD, Zoe Lees iD, Rebecca Rowe iD, Safia Hussain iD, Ehtasham Ahmad iD, Edward Brooke iD, Sophie Dix iD, Catriona Maybury iD

Diabetes, Obesity and Metabolism · 2026-10 · 28 (10) · 9621-9632

DOI: 10.1111/dom.71067 ↗

Auf einen Blick

Tirzepatid war in dieser britischen Kohorte mit deutlichem Gewichtsverlust verbunden. Bei 6 Monaten lag der mittlere Gewichtsverlust bei -13,5 %.

Fragestellung

Wie wirksam ist Tirzepatid im Versorgungsalltag bei Erwachsenen mit Adipositas über einen britischen digitalen Verordnungsdienst?

Methode

Retrospektive Kohortenstudie bei Erwachsenen, die zwischen März 2024 und Juli 2025 Tirzepatid wegen Adipositas begannen; Auswertung von Verordnungs- und Selbstauskunfts-Daten.

Ergebnisse

Bei 6 Monaten betrug der mittlere Gewichtsverlust -13,5 % (95 %-KI -13,56 bis -13,51) und bei 12 Monaten -17,4 % (95 %-KI -17,5 bis -17,3). 89,9 % erreichten ≥ 5 % und 72,1 % ≥ 10 % Gewichtsverlust.

Schlussfolgerung der Autor:innen

Tirzepatid war mit erheblichem Gewichtsverlust und berichteten Vorteilen bei Stimmung und Mobilität verbunden. Kontinuität der Behandlung hing mit Wirksamkeit zusammen; eine maximale Dosissteigerung war oft nicht nötig.

Kernaussagen

  • Mittlerer Gewichtsverlust nach 6 Monaten: -13,5 %
  • 89,9 % erreichten ≥ 5 % und 72,1 % ≥ 10 % Gewichtsverlust
  • Berichtet wurden Verbesserungen bei Mobilität und Stimmung

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Journal article in Diabetes, Obesity and Metabolism, published online on 2026-08-06. Written by Onayomi Rosenior-Patten and 7 co-authors. Institution: HeliosX Group, Leamington Spa, Warwickshire, UK. Major MEDLINE topics: Tirzepatide, Obesity, Anti-Obesity Agents. Cited 3 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

Auf einen BlickAbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Tirzepatide has demonstrated substantial weight‐loss efficacy in clinical trials, but real‐world evidence from routine digital prescribing remains limited.

Methods

We conducted a retrospective cohort study of adults initiating tirzepatide for obesity via a UK digital prescribing service between March 2024 and July 2025. Linked order‐level prescribing data and self‐reported weights were analysed to estimate percentage weight change at 3, 6, 9, and 12 months. Adherence was assessed using mean days between medication orders. A 6‐month survey captured patient‐reported outcomes including lifestyle changes and side effects. The primary endpoint was percentage weight change at 6 months.

Results

Following analysis of 630 545 eligible patients (80.3% female, mean BMI 36.1 kg/m 2 [SD 5.8]), mean weight loss in those with recorded weights was −13.5% (95% CI: −13.56 to −13.51) at 6 months ( n = 270 309) and −17.4% (95% CI: −17.5 to −17.3) at 12 months ( n = 58 434). At 6 months, 89.9% achieved ≥ 5% weight loss and 72.1% achieved ≥ 10%. More regular ordering cadence was associated with greater weight loss, and clinically meaningful outcomes were frequently achieved without escalation beyond intermediate doses. Treatment persistence was higher among patients from less deprived areas, with 26.1% more prescription orders than those from the most deprived areas. Patients reported improvements in mobility (46.7%) and mood (45.9%), and reduced alcohol consumption (26.7%).

Conclusions

Tirzepatide was associated with substantial weight loss and significant patient‐reported benefits including mood and mobility improvement. Treatment continuity was a correlate of effectiveness, and maximal dose escalation was often unnecessary. These findings support the effective delivery of GLP‐1 medication for the treatment of obesity via digital prescribing pathways.

Subjects

MeSH terms (MEDLINE)

TirzepatideObesityAnti-Obesity AgentsHumansFemaleUnited KingdomRetrospective StudiesMaleMiddle AgedWeight LossAdultTreatment OutcomeDigital HealthAgedCohort Studies

Author keywords

GLP‐1TirzepatideUKadherenceobesityreal‐world evidencetreatment patternsweight loss

Substances

TirzepatideAnti-Obesity Agents

Authors and institutions

  • HeliosX Group, Leamington Spa, Warwickshire, UK.
  • University Hospitals of Leicester NHS Trust, Leicester, UK.

ORCID profiles: Onayomi Rosenior-Patten, Zoe Lees, Rebecca Rowe, Safia Hussain, Ehtasham Ahmad, Edward Brooke, Sophie Dix, Catriona Maybury

Cite

APA

Rosenior-Patten, O., Lees, Z., Rowe, R., Hussain, S., Ahmad, E., Brooke, E., Dix, S., & Maybury, C. (2026). Real‐World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort. Diabetes, Obesity and Metabolism, 28(10), 9621-9632. https://doi.org/10.1111/dom.71067

Vancouver

Rosenior-Patten O, Lees Z, Rowe R, Hussain S, Ahmad E, Brooke E, et al. Real‐World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort. Diabetes, Obesity and Metabolism. 2026;28(10):9621-9632. doi:10.1111/dom.71067

BibTeX
@article{RoseniorPatten2026,
  author = {Rosenior-Patten, Onayomi and Lees, Zoe and Rowe, Rebecca and Hussain, Safia and Ahmad, Ehtasham and Brooke, Edward and Dix, Sophie and Maybury, Catriona},
  title = {Real‐World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {10},
  pages = {9621--9632},
  doi = {10.1111/dom.71067}
}
Start for free →